Bingyang Shi

Associate Professor

  • Source: Scopus
  • Calculated based on no. of publications stored in Pure and citations from Scopus
20092021

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

With the award of a competitive Macquarie University Research Fellowship in 2014, I relocated to Macquarie Uni (MQ) to lead a new Brain Drug Delivery Group. There I chase my research dream and ambition to address one of the major challenges for brain disease therapy which is the successful delivery of therapeutic agents across the Blood Brain Barrier (BBB) – the BBB acts as a cellular barrier that prevents toxins, foreign materials and other dangerous molecules from entering the brain, however as a consequence this poses major challenges for getting therapeutic molecules into the brain.

To overcome this, my research program is developing advanced brain drug delivery system to efficiently transport the therapeutic drug across BBB into Brain for preclinical brain disease therapy evaluation with three core research streams: 1) development of novel nanoparticle-based blood–brain barrier (BBB) penetration mechanisms; 2) development of brain delivery systems based on the BBB mechanisms discovered in stream 1; 3) preclinical evaluation of therapies for brain diseases based on the delivery systems developed in stream 2. Each research stream is led by an outstanding ECR team member managing 1-2 PhD students, but I maintain overall stewardship by weekly meetings with my ECR team and students to ensure progress remains on track.

I contributed my expertise & knowledge to develop a new Blood-Brain-Barrier (BBB) penetration mechanism, as well as pioneering new strategies for brain drug delivery that led to an NHMRC Peter Doherty Fellowship (GNT1111822) and NHMRC-ARC Dementia Research Development Fellowship (GNT1111611) (Declined the former and took the Dementia one). In 2016, I discovered a novel glucose-transporter-mediated BBB penetration pathway and drug-controlled-release strategy in neuron, developing an effective brain delivery strategy (Glu-NPs; 2017) and attracting a Mason Foundation grant (GNT MAS2017F034) and NHMRC Project Grant (GNT1166024) for dementia therapy (both CIA; 2018). I lead a multidisciplinary team across MQ (myself, brain delivery; Dr Wright, Alzheimer’s disease (AD) biochemistry) and Western Sydney U (Dr. Chesworth, AD mouse behavior) for these funded projects.

Inspired by the unique capabilities of natural cells, I developed another novel biomimetic brain delivery strategy (Bio-NPs) with outstanding therapeutic effects for brain tumor therapy, which led to Australian Government Endeavour Research Fellowship (Recipient ID:6917_2018) to support visit Harvard University for six months to explore the potential applications in brain metastatic brain cancer therapy. Accordingly, I successfully secured an international grant as CIA ($620K AUD, GNT2018YFA0209800) to support a Phase 1 clinical trial. From 2019, I have been leading a 2nd multidisciplinary team across MQ, Henan province hospital, Huashan Hospital and Harvard Medical School for this project.

In recognizing my significant contributions to my research program, I was awarded four competitive fellowships(Macquarie University Research Fellowship, NHMRC Peter Doherty Fellowship, Australian Government Endeavour Research Fellowship, NHMRC-ARC Dementia Research Development Fellowship), many prestigious awards, eg, American Chem Society Rising star Award and MQ Early Career Researcher of the year in 2019.

Fingerprint

Dive into the research topics where Bingyang Shi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 3 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.
If you made any changes in Pure these will be visible here soon.